Literature DB >> 2693029

A supplementary infusion of glucose-dependent insulinotropic polypeptide (GIP) with a meal does not significantly improve the beta cell response or glucose tolerance in type 2 diabetes mellitus.

I R Jones1, D R Owens, J Vora, S D Luzio, T M Hayes.   

Abstract

Newly diagnosed, previously untreated patients with type 2 diabetes mellitus (n = 6) were studied on two separate days after overnight fasts. On each day they were given a 500-kcal mixed meal plus an infusion of either porcine glucose-dependent insulinotropic polypeptide (GIP) (0.75 pmol/kg/min) or control solution (CS) from 0 to 30 min in random order. Frequent measurements of plasma glucose, C-peptide, insulin and GIP concentrations were made. Fasting GIP levels were similar on both days. During the meal plus GIP infusion plasma GIP levels increased from a basal value of 7.6 +/- 1.5 pmol/1 to a peak of 88.6 +/- 5.4 pmol/1 at 30 min. Following the meal infusion of CS GIP increased from a fasting level of 10.3 +/- 1.2 pmol/1 to a significantly lower peak of 58.0 +/- 8.3 pmol/1 at 60 min. During the meal plus GIP infusion GIP levels were higher at 10-45 min and at 90 min (P less than 0.05-0.001). Fasting and postprandial glucose, C-peptide and insulin levels were, however, similar on both study day. A supplementary infusion of porcine GIP with a mixed meal did not significantly alter the beta cell response or glucose tolerance in this group of patients with type 2 diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2693029     DOI: 10.1016/0168-8227(89)90014-4

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  2 in total

1.  Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose.

Authors:  Matthew R Hayes; Elizabeth G Mietlicki-Baase; Scott E Kanoski; Bart C De Jonghe
Journal:  Annu Rev Nutr       Date:  2014-04-10       Impact factor: 11.848

2.  Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes.

Authors:  Peggy Soule Odegard; Anthony Desantis
Journal:  Diabetes Metab Syndr Obes       Date:  2009-07-31       Impact factor: 3.168

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.